公开(公告)号：US11919959B2

公开(公告)日：2024-03-05

申请号：US16992497

申请日：2020-08-13

Applicant: Cancer Research Technology Limited

Inventor： Roy Bicknell ,  Peter Noy ,  Kabir Ali Khan

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  G01N33/50 ,  A61K39/00

CPC classification number: C07K16/2851 ,  A01K67/0278 ,  A61P35/00 ,  C07K16/30 ,  G01N33/5008 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/0375 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/76

Abstract: The invention provides a method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitor may be an antibody, a polypeptide, a peptide, a polynucleotide, a peptidomimetic, a natural product, a carbohydrate, an aptamer or a small molecule.

公开(公告)号：US20240062898A1

公开(公告)日：2024-02-22

申请号：US18007670

申请日：2021-06-04

Applicant: Cancer Research Technology Limited

Inventor： Geoff Macintyre ,  James Brenton ,  Anna Piskorz ,  Florian Markowetz

IPC: G16H50/20 ,  G16B20/10

CPC classification number: G16H50/20 ,  G16B20/10 ,  G16H10/40

Abstract: The present invention provides methods for predicting the treatment response of a cancer patient, using a tumour copy number profile for the patient. The method comprise analysing the copy number profile to assess whether the characteristics of at least one copy number feature are indicative of the presence of focal amplifications in the tumour genome, wherein the at least one copy number feature is selected from: copy number change-point, segment size and segment copy number. The patient is predicted as being likely to be resistant to treatment with an agent that induces the formation of micronuclei (e.g. doxorubicin) if the characteristics of the at least one copy number features are indicative of the presence of focal amplifications in the tumour genome. Also provided a related methods and systems.

公开(公告)号：US11879014B2

公开(公告)日：2024-01-23

申请号：US16494962

申请日：2018-03-03

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Josephine Salimu ,  Kevin Moulder ,  Beatriz Goyenechea Corzo ,  Pascal Merchiers ,  Sergio Quezada ,  Karl Peggs ,  Frederick Arce Vargas ,  Isabelle Solomon

IPC: C07K16/28 ,  A61K39/00 ,  C07K14/55 ,  A61K45/06

CPC classification number: C07K16/2866 ,  C07K14/55 ,  C07K16/2818 ,  A61K39/0011 ,  A61K45/06 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/60 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.

公开(公告)号：US20240009483A1

公开(公告)日：2024-01-11

申请号：US18011323

申请日：2021-06-28

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Frank van den Heuvel

IPC: A61N5/10 ,  G16H20/40

CPC classification number: A61N5/103 ,  A61N5/1064 ,  G16H20/40

Abstract: We describe a method and a computer system for analysing a radiation treatment plan using a dose of flash radiation to irradiate a volume within a patient and a radiation treatment system using the same. The computer system comprises a processor which is configured to obtain oxygen pressure information for the volume to be irradiated; obtain parameters from a patient treatment plan; input the obtained oxygen pressure information and parameters in to a model which predicts complex damage within the irradiated volume caused by the dose of flash radiation; output a prediction, using the model, of the complex damage caused within the volume by the dose of flash radiation; and quantify, using the prediction, a level of damage to healthy tissue within the irradiated volume. Complex damage is damage which is more complex than a double strand break within DNA in patient tissue and the model is a function of energy of particles within the radiation and oxygen pressure which varies with time.

公开(公告)号：US20240000835A1

公开(公告)日：2024-01-04

申请号：US18038581

申请日：2021-11-24

Applicant: Cancer Research Technology Limited

Inventor： Francis MUSSAI ,  Carmela De Santo

IPC: A61K35/17 ,  C12N5/0783 ,  C07K14/435 ,  C07K16/30 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C12N5/0646 ,  C07K14/435 ,  C07K16/3084 ,  C07K16/2803 ,  A61P35/00 ,  A61K39/4631 ,  A61K39/4613 ,  A61K39/4611 ,  A61K39/464411 ,  C07K16/2863 ,  A61K39/464404 ,  A61K39/464471 ,  A61K2239/28 ,  A61K2239/13

Abstract: The invention relates to nucleic acid constructs comprising a combination of a first sequence encoding a CAR and second sequence encoding an amino acid transporter, and to cells comprising such nucleic acid constructs. It also relates to methods of manufacturing said cells, and to pharmaceutical compositions comprising said nucleic acid constructs or cells, for use in the treatment of diseases with cellular amino-acid depletion such as cancer.

公开(公告)号：US11851494B2

公开(公告)日：2023-12-26

申请号：US16979931

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00 ,  C07K14/05

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/05 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US11814434B2

公开(公告)日：2023-11-14

申请号：US16979930

申请日：2019-03-13

Applicant: Tusk Therapeutics Ltd. ,  Cancer Research Technology Limited

Inventor： Anne Goubier ,  Beatriz Goyenechea Corzo ,  Josephine Salimu ,  Kevin Moulder ,  Pascal Merchiers ,  Mark Brown ,  James Geoghegan ,  Bianka Prinz ,  Sergio Quezada

IPC: C07K16/28 ,  A61P35/02 ,  C12N15/85 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2866 ,  A61K39/39533 ,  A61K39/39541 ,  A61K39/39558 ,  A61K39/39566 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07K14/55 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/85 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2015/8518

Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25, in particular an anti CD25-a-672 antibody which do not block the binding of CD25 to IL-2 or IL-2 signalling. The claimed antibody binds to the epitopes: PHATFKAMA YKEGTM (42-56) and YQCVQGYRALH (150-160) on CD25. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical compositions and methods of treatment, in particular for treating cancer.

公开(公告)号：US11787792B2

公开(公告)日：2023-10-17

申请号：US17124606

申请日：2020-12-17

Applicant: Cancer Research Technology Limited

Inventor： Ian Collins ,  Thomas Peter Matthews ,  Tatiana Faria Da Fonseca McHardy ,  James Osborne ,  Michael Lainchbury ,  Michael Ian Walton ,  Michelle Dawn Garrett

IPC: C07D413/14 ,  A61P35/00 ,  A61P35/02 ,  A61K31/5377 ,  C07D413/02 ,  C07D401/12 ,  A61K9/00 ,  A61K31/4745 ,  A61K31/7068 ,  A61K45/06

CPC classification number: C07D413/14 ,  A61K9/0053 ,  A61K31/4745 ,  A61K31/5377 ,  A61K31/7068 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  C07D401/12 ,  C07D413/02

Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds (referred to herein as “TFM compounds”) which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or a thymidylate synthase (TS) inhibitor; (d) a microtubule targeted agent; (e) ionising radiation; (f) an inhibitor of a mitosis regulator or a mitotic checkpoint regulator; (g) an inhibitor of a DNA damage signal transducer; or (h) an inhibitor of a DNA damage repair enzyme.

公开(公告)号：US20230277492A1

公开(公告)日：2023-09-07

申请号：US18174706

申请日：2023-02-27

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Oliver Maddocks ,  Karen Vousden

IPC: A61K31/198 ,  A61P35/00 ,  A61K9/00 ,  A61K45/06

CPC classification number: A61K31/198 ,  A61P35/00 ,  A61K9/0056 ,  A61K9/0095 ,  A61K45/06

Abstract: The present invention relates to a dietary product comprising a plurality of amino acids, wherein the dietary product comprises all the essential amino acids and wherein the dietary product is substantially devoid of at least two non-essential amino acids; methods and uses thereof in the treatment of cancer; stratification methods and biomarkers for such applications.

公开(公告)号：US20230167443A1

公开(公告)日：2023-06-01

申请号：US17911184

申请日：2021-03-16

Applicant: Cancer Research Technology Limited

Inventor： Iain Alasdair RUSSELL

IPC: C12N15/113 ,  C12N15/10 ,  C12N9/22

CPC classification number: C12N15/113 ,  C12N15/102 ,  C12N9/22 ,  C12N2310/20 ,  C12N2320/11

Abstract: The invention provides methods of selecting guide RNA sequences, and the use of such sequences in CRISPR-Cas gene editing of a target sequence. In particular, the invention relates to a method of selecting guide RNA sequences, based on the determined frequencies of editing outcomes, which in one case result in low mosaicism and in another case result in large deletions or knockouts.